



**ISCHEMIC HEART DISEASE
ACUTE CORONARY SYNDROME**

**Prof Akram Saleh
Consultant Invasive Cardiologist
Jordan University Hospital**

26-9-023

Case presentation

A 50 year old male presented to emergency room complaining of sudden severe chest pain of 1 hour duration. It is retrosternal, compressive, and radiated to left shoulder and arm.

Associated with sweating, nausea and vomiting

On examination: patient is anxious, in pain, sweaty.


BP: 100/60. PULSE: 120 BPM, RR: 26/min

Chest: basal crepitations

What is the most likely diagnosis

pathophysiology

The Spectrum of Myocardial Ischemia




Acute Coronary Syndrome

The spectrum of clinical conditions ranging from:

- **STEMI (Q-wave MI): Total occlusion**
- **NSTEMI (non-Q wave MI): Subtotal occlusion**
- **unstable angina: Subtotal occlusion**

Characterized by the common pathophysiology of a disrupted atherosclerotic plaque (rupture, erosion, or fissure)

Acute Coronary Syndromes



Case presentation

A 50 year old male presented to emergency room complaining of sudden severe chest pain of 1 hour duration. It is retrosternal, compressive, and radiated to left shoulder and arm.

Associated with sweating, nausea and vomiting

On examination: patient is anxious, in pain, sweaty.

BP: 100/60. PULSE: 120 BPM, RR: 26/min


Chest: basal crepitations

The most likely diagnosis is Myocardial infarction


Pathophysiology??

Characteristics of Unstable(RUPTURE-PRONE PLAQUE) and Stable Plaque


Unstable




Stable



Pathogenesis of ACS



Platelet Cascade in Thrombus Formation



Handin RI. *Harrison's Principles of Internal Medicine*. Vol 1. 14th ed. NY, NY: McGraw-Hill; 1998:339-345.

Schafer AJ. *Am J Med*. 1996;101:199-209.


Resting State



Endothelium Disruption


Platelet Adhesion

(via von Willebrand factor)



Platelet Activation


Coagulation Cascade



Platelet Recruitment & Activation



Platelet Aggregation




Thrombus Formation

← Thrombolytics

Abbreviations


- | | | |
|------------------------------------|--|-----------------|
| AA: Arachidonic Acid | PAF: Platelet Activating Factor | X: Factor X |
| ADP: Adenosine Diphosphate | PAR-1: Protease-Activated Receptor-1 | Xa: Factor Xa |
| AT III: Antithrombin III | PAR-4: Protease-Activated Receptor-4 | II: Factor II |
| ASA: Aspirin | P ₂ Y ₁ and P ₂ Y ₁₂ : Purinoreceptors for ADP | IIa: Factor IIa |
| GP IIb/IIIa: Glycoprotein IIb/IIIa | TxA ₂ : Thromboxane A ₂ | |
| LMWH: Low Molecular Weight Heparin | UFH: Unfractionated Heparin | |

Platelet Adhesion, Activation, and Aggregation



IT IS IMPORTANT TO INHIBIT BOTH ACTIVATION & AGGREGATION

(UFH, LMWH, Bivalirudin, Fondaparinux, Enoxaparin)



Abbreviations		
AA: Arachidonic Acid	LMWH: Low Molecular Weight Heparin	UFH: Unfractionated Heparin
ADP: Adenosine Diphosphate	PAF: Platelet Activating Factor	P ₂ Y ₁ and P ₂ Y ₁₂ : Purinoreceptors for ADP
ASA: Aspirin	PAR-1: Protease-Activated Receptor-1	TxA ₂ : Thromboxane A ₂
GP IIb/IIIa: Glycoprotein IIb/IIIa	PAR-4: Protease-Activated Receptor-4	

PATHOGENESIS OF ACS

Plaque rupture

THROMBOSIS

1- Primary hemostasis: Initiated by platelet
platelets adhesion, activation, and aggregation—platelet plug

2- Secondary hemostasis:
activation of the coagulation system—fibrin clot.

These two phases are dynamically interactive:


Platelet can provide a surface for coagulation enzymes

Thrombin is a potent platelet activator

Evolution of Infarction/Necrosis

Coronary Artery Occlusion: The Evolution of Infarction

Progression of myocardial necrosis with time since occlusion



Adapted from Saltissi S, Mushahwar SS. *Postgrad Med J.* 1995;71:534-541, with permission.

ACUTE MYOCARDIAL INFARCTION

THE MOST COMMON CAUSE OF DEATH
RUPTURE ATHEROMATOUS PLAQUE---CORONARY OCCLUSION

Clinical Manifestation:

Chest pain: usually at rest, early morning
> 30 minutes (site, radiation, severity, character,
radiation, associated phenomena..)

painless MI (10-15%): DM, elderly

Present as: Hypotension, Heart failure, Arrhythmia

Physical Examination:

anxious, stressed, sweaty

vital sign: BP, Pulse, Temp

auscultation: S4,S3, Murmure, Rub



Symptoms of Angina



Angina can spread anywhere between the belly button and the jaw, including to the shoulder, arm, elbow or hand- usually on the left side.



Diagnosis of Myocardial Infarction

1-History

2-ECG (Electrocardiogram): **STMI** and **NSTMI**

Hyperacute T wave

ST-segment elevation

Q- wave

T- inversion

ST-segment depression

normal ECG will not exclude MI

3-Cardiac Marker: Troponin,CPK, myoglobin,..

Troponin T,I: 4-6 Hr (**HsT 2-4 hr**)


last 10-14 days

CPK:4-6 Hr, peak 17-24hr, normal 72 hr

MB(MM,BB)

MB2/MB1 >1.5

Regions of the Myocardium




Inferior
II, III, aVF


Lateral
I, AVL,
V5-V6

**Anterior /
Septal**
V1-V4



56 YEAR MALE, C/O: CHEST PAIN OF 2 HRS. WHAT IS THE DIAGNOSIS?



WHAT IS THE DIAGNOSIS?



56 YEAR MALE, C/O: CHEST PAIN OF 2 HRS. WHAT IS THE DIAGNOSIS?



ECG Criteria for Significant ST-segment elevation


V2-V3 Leads:

Men \geq 40 years	\geq 2 mm
\leq 40 years	\geq 2.5 mm

Women	\geq 1.5 mm
-------	---------------

\geq leads 1mm IN at least two other adjacent chest or limb leads

LBBB



ECG Criteria for Diagnosis Of STEMI in LBBB

Sgarbossa Criteria

Criterion	Location	Points
Concordant ST-segment elevation ≥ 1 mm	Any lead with positive QRS deflection	5
Concordant ST-segment Depression ≥ 1 mm	V1, V2, or V3	3
Disconcordant ST-segment elevation ≥ 5 mm	Any lead with negative QRS deflection	2

≥ 3 had specificity of 98%
Score of 0 did not excludes STEMI

Cardiac Marker: Troponin,CPK, myoglobin

Troponin T,I:

CPK:

Myoglobin

Troponin:

- Very specific and more sensitive than CK
- Rises 4-6 hours after injury (HsT 2-4 hr)
- Remains elevated for 10-14 days
- Can provide prognostic information
- Unable to detect re-infarction < 2 weeks

Non MI Causes of Troponin Elevation

Tachycardia

PE

Cardiac failure w/ myonecrosis

Cardiac surgery

Myocarditis

Renal failure: troponin I

Shock

Sepsis

CK/MB

Rises 4-6 hours after injury and peaks at 17- 24 hours

- Remains elevated 36-48 hours
- Back to normal 72 hr
- CPK iso-enzymes: MM, BB, **MB**
- $MB2/MB1 >1.5$

- Positive if CK-MB $> 5\%$ of total CK or 2 times normal

- Elevation can be predictive of mortality

- False positives with exercise, trauma, muscle disease, DM, PE


Myoglobin

- Rises 2-4 hours after injury and peaks at 6-12 hours
- Remains elevated 24-36 hours
- Not cardiac specific
- Rise of 25-40% over 2 hours strongly predictive of MI

Biochemical Markers III

Protein	Molecular mass (kD)	First detection	Duration of detection	Sensitivity	Specificity
Myoglobin	16	1.5–2 hours	8–12 hours	+++	+
CK-MB	83	2–3 hours	1–2 days	+++	+++
Troponin I	33	3–4 hours	7–10 days	++++	++++
Troponin T	38	3–4 hours	7–14 days	++++	++++
CK	96	4–6 hours	2–3 days	++	++

Biochemical Markers II



DIAGNOSIS OF MI-CONT

1-CBC: Increase WBC, ESR

2- Increase plasma glucose

3-Serum lipid (< 24 hr)

4-Echocardiogram:nonspecific changes(hypo,
akinesia, dyskinesia

Management of ACS

Primary goals: **Open the blocked artery**

- Decrease amount of myocardial necrosis
- Preserve LV function
- Prevent major adverse cardiac events
- Treat life threatening complications

Management of ACS

Immediate general treatment (**MONAH**)

- **Morphine**

- Analgesia
- Reduce pain/anxiety—decrease sympathetic tone, systemic vascular resistance and oxygen demand
- Careful with hypotension, hypovolemia, respiratory depression

- **Oxygen 2-4 liters/minute**

- Up to 70% of ACS patient demonstrate hypoxemia
- May limit ischemic myocardial damage by increasing oxygen delivery/reduce ST elevation

Management

Immediate general treatment(MONAH)


- **Nitroglycerin sublingual or spray**
 - Dilates coronary vessels—increase blood flow
 - Reduces systemic vascular resistance and preload
 - Contraindications:
 - hypotension, RV infarction ,recent ED meds
 - **Aspirin 160-325mg** chewed and swallowed
 - Irreversible inhibition of platelet activation
 - Stabilize plaque and arrest thrombus
 - Reduce mortality in patients with STEMI
 - Careful with active PUD, hypersensitivity, bleeding disorders

TREATMENT OF MYOCARDIAL INFARCTION

IN EMERGENCY ROOM:



- 1-Rapid assessment
- 2-Establish IV access
- 3-12 ECG
- 4- Aspirin 150-300 mg Orally, Clopidogrel or ticagrelor
- 5-Oxygen
- 6-Analgesia: IV morphine, diamorphine 3-5 mg
- 7-Antiemetic: metoclopramide 10 mg IV
- 8- Heparin 5000 u iv
- 9-Sublingual nitrate: if NO hypotension, RV MI
- 10-ECG monitor
- 11-**Reperfusion**: PCI or Thrombolytics, (CABG)

Time is Muscle!!!




1. Time is Myocardium

2. Infarct Size is Outcome



■ Critical Time-dependent Period **■ Time-independent Period**
Goal: Myocardial Salvage **Goal: Open Infarct-Related Artery**

Reduction in Long Term Mortality





Every 30-minute delay from onset of symptoms to reperfusion. 1 year mortality is increased by 8%


Primary angioplasty

- Coronary arteries: balloon angioplasty

Arrival




After balloon





- The European Society of Cardiology (ESC) guidelines recommend primary PCI as the preferred treatment whenever it is available within 90-120 minutes of the first medical contact





Angioplasty reduces mortality and morbidity

Primary PCI vs. Thrombolysis in ST-Elevation Myocardial Infarction:
Meta-analysis (23 Randomised controlled trials, N=7,739)



Reperfusion in STEMI





Reperfusion: PCI

ST-Segment elevation MI: Reperfusion THROMBOLYSIS/ PCI Time= Muscle

Early reperfusion: **time dependent**

- improve survival
- LV function preservation


TIMI 3 flow

- PCI: 95%, TPA:54%, STREPTO:32%


PCI: Reduce re-occlusion and recurrent thrombosis

TIMI Flow Grade Definitions¹

- TIMI flow grade describes epicardial blood flow:
 - Grade 0: complete occlusion
 - Grade 1: penetration of obstruction with no distal perfusion
 - Grade 2: perfusion of artery with delayed flow
 - Grade 3: full perfusion with normal flow



TFG 0
Occlusion



TFG 1
Penetration



TFG 2
Slow flow



TFG 3
Normal flow

ST Elevation or New LBBB

Step 2: Select Reperfusion Strategy

Fibrinolysis generally preferred if:

- ≤ 3 hours from onset
- PCI not available/delayed
 - Door to balloon > 90 min
 - Door to balloon minus door to needle > 1 hr
- Door to needle goal < 30 min
- No contraindications

Invasive strategy preferred if:

- > 3 hours from onset
- PCI available
- Door to balloon < 90 min
- Door to balloon minus door to needle < 1 hr
- Fibrinolysis contraindications
- High risk
- STEMI dx in doubt
- Age > 75

INDICATIONS TO THROMBOLYTIC THERAPY are ECG Changes

1-ST-elevation:

2 adjacent leads

> 1mm in limb leads (L1, L11, L111, AVF,AVL)

> 2mm in precordial leads (V1-V4)

OR

2- New Left Bundle Branch Block (LBBB)

Common Thrombolytic Regimens for STEMI¹

	Initial treatment	Co-therapy	Contraindications
Streptokinase (SK)	1.5 million U in 100 mL 5% dextrose or 0.9% saline over 30–60 min	None or iv heparin x 24–48 hours	Prior SK or anistreplase
Alteplase (tPA)	15 mg iv bolus, then 0.75 mg/kg over 30 min, then 0.5 mg/kg iv over 60 min Total dose not over 100 mg	iv heparin x 24–48 hours	
Retepase (rPA)	10 U + 10 U iv bolus given 30 min apart	iv heparin x 24–48 hours	
Tenecteplase**** (TNK-tPA)	Single iv bolus 30 mg if <60 kg 35 mg if 60 kg to <70 kg 40 mg if 70 kg to <80 kg 45 mg if 80 kg to <90 kg 50 mg if ≥90 kg	iv heparin x 24–48 hours	

**Note: acetylsalicylic acid (ASA) should be given to all patients without contraindications;
iv=intravenous**

1. Van de Werf F et al. *Eur Heart J* 2003; 24: 28–66.

Current Limitations of Pharmacologic Reperfusion

- **Lack of initial reperfusion in 20-30% of patients¹**
 - **Associated with a 2 X increase in mortality**
- **Reocclusion in 5–8% of patients¹**
 - **Associated with 3 X increase in mortality**
- **Despite current therapy, 10% of STEMI patients die within one month after hospital discharge²**
- **Within 6 years 18% of men and 35% of women will suffer another heart attack³**

1. Sabatine M et al. *New Eng J Med* 2005; 352: 1179–1189.

2. Goldberg RJ et al. *Am J Cardiol* 2004; 93: 288–293.

3. Antman EM et al. 2004 ACC/AHA STEMI Guidelines. Available at:
www.accp.org/clinical/guidelines/stemi/index.pdf. Accessed February 2005.

Contraindications to Thrombolytic Therapy

Absolute contraindication

- 1-Active internal bleeding
- 2-Suspected aortic dissection
- 3-Trauma or surgery < 2 weeks
- 4-History of hemorrhagic CVA
- 5-BP > 200/120 mmHg
- 6-Prolonged CPR
- 7-Recent head trauma or known intracranial neoplasm
- 8-Diabetic proliferative retinopathy
- 9-Pregnancy
- 10-Previous allergy to the thrombolytic agent

Relative contraindication

- 1-Trauma or surgery > 2 weeks
- 2-Active peptic ulcer disease
- 3-History CVA
- 4-Bleeding diathesis or current use of anticoagulant
- 5-Uncontrolled hypertension
- 6-Previous exposure to streptokinase
- 7-Pericardial friction rub
- 8-Significant liver dysfunction

COMPLICATION OF THROMBOLYTIC THERAPY

1-Hemorrhage <5%

2- Systemic embolization

3-CNS bleeding

4-Allergic Reaction 1-3%, anaphylaxis 0.1%

Other Routine Therapies in Acute STEMI¹

- **ASA 150–325 mg (non-enteric coated), Clopidogrel**
- **Beta-blockers**
- **Angiotensin-converting enzyme (ACE) inhibitors**
- **Oxygen**
- **statines**
- **Nitrates**
- **Heparin if indicated**
- **CCU: 24-48 hr**
- **Word: 3-5 days**
- **Home medication: aspirin, B-blocker, statines, ACE I, ? nitrate**

Complications of Myocardial Infarction

1- Arrhythmias: Any type

Ventricular: PVC, VT, Accelerated Idioventricular rhythm, VF

Atrial: AF 15% in ist 24 hr, sinus brady or tachycardia, PAC

Heart Blocks: 1st, 2nd, 3rd block, BBB

2- Heart failure (pump failure). **Killip Classification I-IV**

3-Myocardial rupture: 1st 10 days

free wall, septum, papillary muscle, ventricular pseudoaneurysm

4- Recurrent or extension of MI, Thromboembolism

5-Early pericarditis: ASA(NSAID and Steroids are contraindicated)

6-Dresslers syndrome 2-12 weeks: ASA, Ibuprofen

7- Left ventricular aneurysm

8-Sudden death

Differential Diagnosis of MI

1- Aortic Dissection

2-Massive Pulmonary Embolism

3- Acute pericarditis

PROGNOSIS of MI

pre-hospital mortality:20%

hospital mortality:10-12%

1st year mortality 10%

Poor prognostic features:

1-Heart Failure

2-EF< 40%

3- Large infarction size

4-Anerior MI

5-New BBB

6- Mobits type 2 , and 3rd AV Block

7-Reinfarction or extension of MI

8-Frequent PVC

9-VF or VT

10-Atrial fibrillation

11-Post infarction angina

12-DM

13-Age> 70

14-female

TIMI Risk Score in STEMI

Risk factor	Score
1- Age>65	2
2- Age>75	3
3- Hist of angina	1
4- Hist of hypertension	1
5- Hist of DM	1
6- Syst BP< 100	3
7- Heart rate> 100	2
8- Killip II-IV	2
9- Ant M or LBBB	1
10- Delay treat > 4 hr	1

TIMI Risk Score in STEMI

Total Score	Risk of death at 30 days(%)
0	0.8
1	1.6
2	2.2
3	4.4
4	7.3
5	12.4
6	16.1
7	23.4
8	26.8
9-16	35.9

Post-MI Management

- 1- Risk factors modification (Stop smoking, BP < 140/90, HbA1c < 7, Exercise, ..)**
- 2- Aspirin, Clopidogrel or ticagrelor**
- 3- B-blockers**
- 4- Statines**
- 5- ACE-inhibitors**
- 6- Aldosterone antagonist (in presence of heart failure)**

UNSTABLE ANGINA



Unstable Angina

Definition:

- 1-New onset angina < 8 weeks
- 2- Angina at rest or minimal exertion
- 3-Crescendo angina: **patient with chronic angina with increasing frequency, duration, or intensity of chest pain**
- 4-Post MI or Revascularization angina: 2 weeks

Types:

Pathophysiology: plaque erosion or rupture, vasoconstriction, distal embolisation

Diagnosis: Clinical, ECG , ***Negative cardiac markers***

Unstable Angina Classification

1- Acute: rest pain within the last 48 hr

2- Subacute: no pain within the last 48 hr

1- primary: no secondary causes

**2-Secondary: sever anemia, thyrotoxicosis, hypertension,
arrhythmias**

1-High Risk

2-Low risk

HIGH RISK UNSTABLE ANGINA

1-Rest pain > 20 minutes

2-Accelerating tempo of ischemic symptoms in preceding 48 hr

3-Clinical finding of: pulmonary edema, new S3, new MR,
Hypotension, Brady or Tachycardia

3-ECG changes: transient ST segment changes, BBB, VT

4- DM

Risk Stratification

TIMI Risk Score

Predicts risk of death, new/recurrent MI, need for urgent revascularization within 14 days

1- Age > 65

2- 3 or more cardiac risk factors

3- Prior angiographic coronary obstruction (stenosis \geq 50%)

4- ST segment deviation

5- More than 2 angina events within the previous 24 hours

6- Use of aspirin within previous 7 days

TIMI Risk Score For UA/NSTEMI

Age ≥ 65 years

≥ 3 CAD Risk Factors


Prior Stenosis $>50\%$

ST deviation

≥ 2 Anginal events ≤ 24 hours

ASA in last 7 days

Elevated Cardiac Markers (CK-MB or troponin)



Treatment of HIGH RISK UNSTABLE ANGINA AND NSTMI

1-CCU admission : Treat as MI except for thrombolytics

NO THROMBOLYTICS

2-Aspirin^{***}, Clopidogrel

3-Anticoagulant: heparin (LMWH is superior to unfractionated heparin)^{***}

4- Nitrate (S/L, oral, IV)

5-B-blocker


6-clopidogrel, GP 11b,111a-----Cath PCI(angio)

7-Statines

8- Invasive or conservative management


^{***} *improve prognosis*

Invasive vs Conservative Strategy for UA/NSTEMI




UA, unstable angina, NSTEMI, non-ST-segment myocardial infarction; ISAR, Intracoronary Stenting and Antithrombotic Regimen Trial; RITA, Randomized Intervention Treatment of Angina; VANQWISH, Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital study; MATE, Medicine vs Angioplasty for Thrombolytic Exclusions trial; TACTICS-TIMI18, Treat Angina with Aggrastat® and Determine Cost of Therapy with Invasive or Conservative Strategy; FRISC, Fragmin during InStability in Coronary artery disease.


Normal or non-diagnostic EKG



ST Depression or Dynamic T wave Inversions



Algorithm for Initial Assessment and Evaluation of the Patient with Acute Chest Pain



Thank you

